|
|
|
|
|
HONG KONG, July 10, 2015 - (ACN Newswire) - China Pioneer Pharma Holdings Limited, China's marketing, promotion and channel management service provider dedicated to imported pharmaceutical products and medical devices in China, invited Dr. John Crew, a wound care expert from Seton Medical Center of the US and other expert team to visit victims who suffered burns in the dust explosion in Taiwan, and share with the patients the use of NeutroPhase for the treatment of deep 2nd grade & 3rd grade burns in order to exert the effect of NeutroPhase to the best. Recently, Dr John Crew has already visited National Taiwan University Hospital, Taipei Veterans General Hospital, Mackay Memorial Hospital and Tri-Service General Hospital and delivered his sincere blessings to the patients. As the exclusive distributor for NeutroPhase in mainland China, Taiwan and throughout Southeast Asia, China Pioneer Pharma has provided free NeutroPhase products and related medical advices for the burn victims, promoted more wide usage of NeutroPhase in Taiwan hospitals and help the treatment of burns to avoid deadly wound infection.
On 8th July, Dr. John Crew, together with the chief of Infection Control Center of Seton Medical Center and doctors from National Taiwan University Hospital Infection Control Center held a seminar to discuss the medical cases of NeutroPhase and share the experience of HOCI in the treatment of burns. Moreover, Dr. John Crew together with chief of Plastic Surgery Center of Seton Medical Center and doctors from Plastic Surgery Department of National Taiwan University Hospital discussed about the penetrated power of NeutroPhase, safety for underlying tissue, treatment steps of superficial partial thickness (2nd grade burns) and etc.
On 9th July, Dr. John Crew together with the academic chief of Seton Medical Center gave a theme training to over 70 doctors from Taipei Veterans General Hospital regarding the treatment steps of NetroPhase in superficial partial thickness (2nd grade) and deep partial thickness. Dr. John Crew also shared the use of HOCI in the treatment of 2nd grade burns and discuss the medication contraindications with doctors from Mackay Memorial Hospital. The doctor also gave a presentation of NetroPhase in the treatment of burns to over 40 doctors from Tri-Service General Hospital.
On 10th July, despite the landing of typhoon in Taiwan today, Dr. John Crew still arrive on Taoyuan International Airport and will continue to visit hospitals in Taiwan to share usage and treatment of NeutroPhase in burns. He wishes the soonest recovery of the victims of dust explosion.
About NeutroPhase
NeutroPhase is a new skin wound and cleanser; its active ingredient pure hypochlorous acid is a substance produced naturally by the immune system as a first defense against microbial invaders. This product uses the unique mechanism of HOCl to kill bacterium (Gram-positive bacteria and gram-negative bacteria), fungi and viruses quickly to control infection and neutralize bacterial toxins. It can be widely used in a variety of acute and chronic skin damage treatment including burns to promote wound healing without damaging granulation tissue. NeutroPhase is manufactured by NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY) and China Pioneer Pharma became its exclusive agent in China and Southeast Asia approved by The US Food and Drug Administration (FDA). In Novermber2014, Taiwan Food and Drug Administration (TFDA) approved its sale in Taiwan.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: Aganocide compounds, led by auriclosene, and its Hypochlorous Acid Family of Products, led by NeutroPhase. The Hypochlorous Acid Family of products includes NeutroPhase for wound care, as well as two new recently introduced products: Avenova for the eye care market and CelleRx for the dermatology market.
About China Pioneer Pharma Holdings Limited
China Pioneer Pharma is one of the leading comprehensive marketing, promotion and channel management service providers dedicated to imported pharmaceutical products and medical devices in China. The Group was established in 1996, and was listed on the Main Board of the Hong Kong Stock Exchange (Stock code: 01345) on 5 November 2013. The Company has strategically focused on providing comprehensive marketing, promotion and channel management services to small and medium sized overseas suppliers, and is generally the sole provider of such services in China for the relevant products. China Pioneer Pharma runs a diversified range of imported products (substantially all of which are prescription products), covering ophthalmology, pain management, cardiovascular, respiratory, gastroenterology, immunology and other therapeutic areas and a range of medical devices covering four medical specialties, including ophthalmology, odontology and wound care. The Company has also secured marketing, promotion and sales rights for 14 additional prescription pharmaceutical products and over 20 additional medical devices, which are in the registration process under China Food and Drug Administration for their importation and sales in China. As of 31 December 2014, the Company sold products through its nationwide marketing, promotion and channel management services networks to over 28,500 hospitals and other medical institutions and over 105,000 pharmacies across 31 provinces, municipalities and autonomous regions in China.
Topic: Press release summary
Source: China Pioneer Pharma Holdings Limited
Sectors: Daily Finance, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
|
